Assesses thrombotic risk in myelodysplastic syndrome patients using Luspatercept, suggesting its safety profile.
= 0.13). The incidence of DVT, PE, and stroke was also not statistically significant between the cohorts. In contrast, the incidence of acute myocardial infarction was significantly lower in the Luspatercept cohort (42.6/1000PY vs 65.7/1000 PY; HR (95% CI): 0.67 (0.49-0.91)). In this study, the use of Luspatercept did not increase the risk of VTE as compared to ESAs. These findings reinforce the thrombotic safety of luspatercept.
No takes yet. Share an insight, caveat, or question.
Vojjala et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: